Am J Blood Res. 2020 Dec 15;10(6):355-359. eCollection 2020.
ABSTRACT
INTRODUCTION: Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition. Ibrutinib in association with venetoclax was successfully investigated in a phase II trial.
CASE REPORT: We have retrospectively analyzed 4 patients with R/R MCL receiving daily oral ibrutinib in association with venetoclax. All patients received oral ibrutinib 560 mg per day as monotherapy and subsequently added venetoclax with an initial dose of 50 mg per day, with weekly rump-up until a full dose of 400 mg per day until disease progression. All patients achieved a response, the CR rate was 50%. The aim was to perform an allogeneic SCT (allo-SCT). One patient experienced an early relapse and died because of PD. Allo-SCT was successfully performed in the other 3 patients; ibrutinib and venetoclax were discontinued before allo-SCT. One patient died because of transplant-related complications, while the other 2 cases are alive and in CR. No tumor lysis syndrome occurred.
DISCUSSION: Ibrutinib plus venetoclax represents a promising and feasible treatment option for R/R MCL patients outside clinical trials.
PMID:33489445 | PMC:PMC7811909
No comments:
Post a Comment